Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > Monensin as potential drug for treatment of SLeX-positive tumors
Publication

Publications

Monensin as potential drug for treatment of SLeX-positive tumors

Title
Monensin as potential drug for treatment of SLeX-positive tumors
Type
Another Publication in an International Scientific Journal
Year
2024-03-13
Authors
José Barbosa
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Other information
Authenticus ID: P-017-3QR
Abstract (EN): <jats:title>Abstract</jats:title><jats:p>Colorectal (CRC) and gastric (GC) cancers remain the top lethal cancers and targeted therapies in this setting are still very limited. Sialyl Lewis X (SLeX), a cancer-associated glycan highly expressed in both CRC and GC, plays a crucial role in cancer cell dissemination and metastasis. Thus, presenting a promising but still underexplored therapeutic target. In this work, we performed a high-throughput screening (HTS) approach to identify potential inhibitors of SLeX expression on cancer cells. Two libraries including a total of 7836 compounds were screened and monensin emerged as a promising SLeX inhibitor. Monensin promoted structural alterations in the secretory pathway, particularly at the Golgi apparatus, impacting protein<jats:italic>O</jats:italic>-glycosylation and secretion. RNAseq transcriptomic analysis uncovered significant alterations in Gene Ontology (GO) terms associated with protein misfolding, target to the membrane, as well as, epithelial cell-cell adhesion protein.<jats:italic>In vitro</jats:italic>studies showed that, upon treatment with monensin, SLeX-positive cancer cells showed reduced viability, concomitant with decreased motility and invasive capacities. Using<jats:italic>in vivo</jats:italic>xenograft models of chick embryo chorioallantoic membrane (CAM) and nude mice, revealed that monensin reduced tumor formation and invasion. Pre-clinical validation using gastric cancer patient-derived organoids (PDOs) and organoid xenotransplants in mice further underscored the clinical potential of monensin in suppressing the growth of SLeX- positive tumors. Overall, our findings set the ground for further evaluation of monensin as a novel therapeutic agent in GC and CRC in the clinical setting.</jats:p>
Language: English
Type (Professor's evaluation): Scientific
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same authors

UM CASO RARO DE TUMOR GÁSTRICO SUBMUCOSO (2016)
Poster in a National Conference
José Barbosa
CARCINOMA GÁSTRICO EM DOENTES COM POLIPOSE ADENOMATOSA FAMILIAR (2016)
Poster in a National Conference
José Barbosa
The impact of the prognostic nutritional index in gastric cancer (2019)
Poster in an International Conference
Nogueiro, J; Santos-Sousa, H; Fernandes, C; Sousa, F; Devezas, V; Fonseca, T; Pereira, A; José Barbosa; Costa-Maia, J

See all (107)

Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-07-18 at 00:41:46 | Privacy Policy | Personal Data Protection Policy | Whistleblowing